Precision RNA Therapeutics for Liver Restoration
Starting with liver cancer surgery. Expanding across liver disease.
Apterna is developing precision RNA therapeutics designed to restore liver function in patients whose livers are too damaged for surgery or transplant. Our lead programme begins with liver cancer patients who are denied potentially curative surgery because of poor liver reserve, with the broader goal of addressing liver dysfunction across the disease continuum.
This is not another tumour-directed therapy and not another symptomatic liver treatment. Our approach is designed to help recover core liver function, opening a potential path from palliative management towards curative intervention in selected patients. The same therapeutic logic may also support future expansion into advanced cirrhosis, transplant avoidance, and broader metabolic liver disease.
Built on a validated RNA delivery approach and a focused development strategy, Apterna is advancing a liver-first programme with clear clinical rationale, broad downstream relevance, and significant long-term market potential.
A New Approach to Liver Functional Restoration
Apterna is developing precision RNA therapeutics for patients with advanced liver dysfunction. Our lead programme begins with liver cancer patients denied surgery because their livers cannot tolerate the operation, with future expansion planned across cirrhosis, transplant avoidance, and metabolic liver disease.
Lead Focus
Restoring liver reserve in patients currently unable to access curative liver surgery.
Clinical Vision
Helping move selected patients from limited treatment options towards potentially curative pathways.
Platform Expansion
Designed to extend from surgical enablement into cirrhosis, transplant avoidance, and metabolic liver disease over time.
Apterna is addressing a major unmet need in liver care by developing a programme designed to restore core liver function in patients who currently have few or no curative treatment options. The programme begins with a high-need patient group and has the potential to expand across broader stages of liver disease as evidence builds.
Focused Where the Need Is Greatest.
Millions of patients worldwide suffer from diseases that remain out of reach for current therapies — either because drugs cannot access the target organ or because their toxicity outweighs their benefit.
Liver Surgery Unlock
- Focused initially on patients with liver cancer who are denied potentially curative surgery because their liver function is too poor.
- Designed to help restore liver reserve and expand access to surgery.
- Addresses a major unmet need where no medicine currently solves the underlying liver problem.
Cirrhosis and Transplant Avoidance
- Built for broader relevance in advanced liver dysfunction beyond the initial surgical setting.
- Designed to support liver recovery in patients at risk of progressive decline or transplant dependency.
- Extends the programme into a second major liver market as evidence builds.
Fatty Liver Disease and Obesity
- Positioned for future expansion into the world’s largest liver disease population.
- Designed to complement metabolic therapies when deeper liver repair is still needed.
- Creates long-term relevance across a large and expanding liver disease market.
Additional platform capabilities are available for discussion with qualified partners on a confidential basis.
A New Opportunity in Liver Medicine
Apterna is building a new category of therapy in an area where the clinical need is urgent and the strategic opportunity is substantial. Starting with a focused surgical setting and expanding across broader liver disease, the programme is designed to open curative pathways, support liver recovery, and create relevance across multiple stages of disease progression.
With a proven delivery foundation, a clear translational strategy, and a development model built around early validation and staged progression, Apterna is positioned to advance with both scientific discipline and commercial intent.
What makes this opportunity especially compelling is that Apterna is not entering a crowded category. It is pursuing a new therapeutic approach in an area where current options often treat the tumour, the symptoms, or the metabolic inputs, but do not restore the liver function needed to reopen curative pathways. That creates relevance not only for the initial surgical setting, but also for broader liver disease over time, while remaining complementary to established clinical practice rather than requiring it to change.
Building the Furure of RAN Medicine Together
Apterna combines focused scientific development with a build-to-partner strategy designed for disciplined growth. The programme is being advanced through the key value-creating stages internally, with future strategic collaboration intended to support broader clinical development, scale, and global reach.
What strengthens this model is not only the science, but the way the programme has been structured from the outset. It is built around a validated therapeutic modality, staged go/no-go decision points, and an intellectual property strategy designed to support future licensing, partnership, and long-term platform value.
Apterna is led by a team with experience across RNA therapeutics, clinical development, regulatory execution, company building, and strategic partnering. That combination gives the company both scientific credibility and a practical path towards translation, execution, and collaboration with the right long-term partners.
We welcome engagement from strategic partners and qualified investors interested in the future of liver-directed RNA therapeutics. Additional information is available on a confidential basis.
Why Apterna Stands Out
FIRST-OF-ITS-KIND FOCUS
Apterna is advancing a new category of liver medicine designed to restore liver function in patients whose liver reserve currently limits access to curative treatment.
Starting with liver cancer surgery, the programme is built to expand across broader liver disease over time.
LARGE AND EXPANDING OPPORTUNITY
The business starts with a focused, provable entry point, then extends into cirrhosis, transplant avoidance, and fatty liver disease.
Together, these markets represent a substantial long-term opportunity exceeding £37 billion by 2035.
DISCIPLINED DEVELOPMENT MODEL
Apterna is building on a validated RNA therapeutic foundation with a staged go/no-go progression designed to resolve key risks early.
The programme is structured for efficient development, selective partnering, and long-term strategic value creation.
Built for Strategic Collaboration
Apterna is advancing a focused liver-first programme with the aim of creating meaningful clinical and strategic value through disciplined development. Our model is designed to progress through key proof-of-concept milestones internally, then expand through the right strategic partnerships for broader clinical development, scale, and reach.
We welcome conversations with strategic partners, specialist collaborators, and qualified investors who share our interest in advancing a new approach to liver medicine. Further information is available on a confidential basis.